ClinicalTrials.gov
Cure8 trial brief
Why This Matters
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could affect postoperative treatment choices.
Who Should Pay Attention
Adult Crohn's patients post‑surgery; gastroenterologists and colorectal surgeons; researchers focused on postoperative recurrence and biologic therapies.
Study Snapshot
Story typeClinical Reference
Evidence typeClinical trial
Enrollment198 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
The study will include about 198 adults who had intestinal resection and began prophylactic biologic therapy within six weeks after surgery. Patients are grouped as anti‑TNF (infliximab, adalimumab) versus non‑anti‑TNF (vedolizumab, ustekinumab). The primary outcome is endoscopic recurrence (Rutgeerts score ≥ i2) assessed by ileocolonoscopy at 6–12 months.
Secondary outcomes include severe endoscopic and clinical recurrence, rehospitalization, reoperation, drug persistence, and pathological changes. The study uses retrospective real‑world data and plans multivariable regression and survival analyses; it does not assign treatments.
Results, if published, would inform choice of postoperative biologic therapy but will reflect observational design limitations.
Keep In Mind
This is a retrospective cohort using routine clinical data, so findings will be subject to confounding and selection biases. The registry describes planned methods and outcomes but does not report results.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
Trial IDNCT07694674
Study typeObservational
Enrollment198 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedJul 10, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
When are biologic drugs an option for Crohn’s disease?
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
Crohn's Disease Market Across The 7MM To Witness Upsurge In Growth From USD 9 Billion In 2023
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.